We're unable to sign you in at this time. Please try again in a few minutes.
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Letters |

Prostacyclin and Thromboxane and the Development of Preeclampsia

Ariela Benigni, ScD; Giuseppe Remuzzi, MD
JAMA. 2000;283(12):1568-1569. doi:10.1001/jama.283.12.1563.
Text Size: A A A
Published online


To the Editor: Dr Mills and colleagues1 reported reduced prostacyclin (PGI2) production in the face of unchanged thromboxane A2 (TxA2) generation in pregnant women 3.5 to 4 months before clinical onset of preeclampsia. This is exactly what we described 10 years ago in a longitudinal study aimed at systematically measuring TxA2 and PGI2 urinary metabolites in healthy pregnant women and in subjects at risk of developing pregnancy-induced hypertension.2 We showed that urinary excretion of 6-keto (PGF) was significantly reduced (by 42%) in women at risk of developing preeclampsia compared with healthy pregnant women as early as 12 weeks of gestation and remained lower at 16 weeks (by 48%), 24 weeks (by 30%), and until term (by 43%). By contrast, urinary thromboxane B2 (TxB2) excretion was fairly similar in women at risk of preeclampsia and in those with normal pregnancy. Consequently, the ratio of TxB2 and 6-keto PGF was higher as early as 12 weeks in women at risk of pregnancy-induced hypertension over normal pregnancy (TxB2/6-keto PGF: 0.75 vs 0.4 g) and remained as such at term.


Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

First Page Preview

View Large
First page PDF preview




Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.


Some tools below are only available to our subscribers or users with an online account.

0 Citations

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

Related Content

Customize your page view by dragging & repositioning the boxes below.